| For: | Ascari S, Chen R, De Sinno A, Stefanini B, Cescon M, Serenari M, Mosconi C, Tovoli F. Post-immunotherapy second-line strategies for hepatocellular carcinoma: State of the art and ongoing trials. World J Gastroenterol 2026; 32(3): 111528 [PMID: 41640611 DOI: 10.3748/wjg.v32.i3.111528] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v32/i3/111528.htm |
| Number | Citing Articles |
| 1 |
Xiaokun Liu, Xiao Gao, Yuling Yang, Di Yang, Yani Sun, Yuxuan Yang, Tao Zhao, Ning Li. Unraveling regorafenib resistance: metabolic reprogramming, tumor plasticity, and novel approaches to overcome therapy failure. Archives of Pharmacal Research 2026; 49(4) doi: 10.1007/s12272-026-01612-1
|
| 2 |
Dhiraj Agrawal, Dinesh Jothimani, Sherrie Bhoori, Guru N. Reddy, Sanjiv Saigal, Mohamed Rela, Vincenzo Mazzaferro. Immune-checkpoint inhibitors for advanced hepatocellular carcinoma in Child–Turcotte–Pugh-B cirrhosis: a liver-centric approach to outcomes beyond tumor progression. Hepatology International 2026; doi: 10.1007/s12072-026-11097-1
|
| 3 |
Daichi Takizawa, Hirotaka Arai, Mitsuhiko Shibasaki, Yuki Tamura, Satoru Kakizaki, Takeshi Hatanaka, Atsushi Naganuma, Takashi Ueno, Toru Fukuchi, Masashi Namikawa, Satoshi Takakusagi, Shuichi Saito, Takayoshi Suga, Hiroki Tojima, Yuichi Yamazaki, Toshio Uraoka. Efficacy of Lenvatinib as Second-Line Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma. Current Oncology 2026; 33(3) doi: 10.3390/curroncol33030159
|